Refine by
Antigen Receptor Suppliers & Manufacturers
29 companies found
based inSan Diego, CALIFORNIA (USA)
TGT´s mission is to provide eco-friendly products and systems that affect the world in a positive and beneficial way in the areas of soil and water, two of the three cornerstones of all life. Terawet was originally founded with the intent of ...
based inCambridge, MASSACHUSETTS (USA)
Alphageneron Pharmaceuticals is a clinical-stage biopharmaceutical company developing autologous and allogeneic Natural Killer cells (NK) cell and antibody-based therapies to treat cancer. Our seasoned team of biopharmaceutical executives, ...
Chimeric Antigen Receptor (CAR) NK Cells: Alphageneron is developing ‘off-the- shelf’ umbilical cord (UC) blood- and induced pluripotent stem cell (iPSC)-derived CAR-engineered NK (CAR NK) cell-based ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
We are developing CYNK-101 as a combination treatment for multiple cancer indications. CYNK-101 is manufactured from a specific type of immune cell, NK cells, that we extract from postpartum placentas and then genetically engineer to increase cell ...
based inKöln, GERMANY
Singleron Biotechnologies is an innovative molecular diagnostic company dedicated to applying groundbreaking single cell analysis techniques in clinical diagnosis, drug development, and health management. Singleron Biotechnologies is an innovative ...
Singleron's sCircle technology enables full length V(D)J region sequencing at single cell level with short-read ...
based inNotting Hill, AUSTRALIA
Cartherics is developing its novel “off-the-shelf” (allogeneic) immune therapy products for the treatment of cancer based on immune killer cells. The company is developing large-scale manufacture of these CAR-iNK cells for application in human ...
This technology involves induced pluripotential stem cell (iPSC) derived NK cells (and, potentially, other types of immune cells). iPSCs have unlimited capacity for ...
based inShirley, NEW YORK (USA)
After decades of research and accumulation, Creative Biolabs has become a leader in the discovery and manufacturing of recombinant antibodies (rAbs), providing the most reliable and qualified services to customers in academia and industry around the ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family. Dual targeting of 4-1BB and OX40 provides synergistic ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
PRT062607 (P505-15) Hydrochloride is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 Hydrochloride exerts potent antitumor activity in tumor xenograft mouse ...
based inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
The chimeric T cell antigen receptor therapy, also known as CAR-T, is an immunotherapy that is innovating the treatment of hematological and solid tumors. This new technology is considered less aggressive than ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet ...
based inCambridge, MASSACHUSETTS (USA)
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with ...
Our first ex vivo development candidate seeks to treat acute myeloid leukemia (AML) by engineering autologous T cell receptors (TCR) directed towards the Wilms’ Tumor 1 (WT1) antigen, an over-expressed protein ...
based inCambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...
A small portion of these cells are collected, from a patient’s blood sample, and re-engineered to produce chimeric antigen receptors (CAR’s) on the cell surface. The chimeric antigen ...
based inOxford, UNITED KINGDOM
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen ...
ProM1™ MHC Class I Monomers, biotin labeled enabling specialist assays for defined MHC Class I peptide target ...
based inSan Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell ...
based inMawson Lakes, AUSTRALIA
Carina Biotech is an Australian pre-clinical immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. CAR-T therapy is a revolutionary new treatment option that uses a ...
based inMinneapolis, MINNESOTA (USA)
Bio-Techne empowers researchers in Life Science and Clinical Diagnostics by providing high-quality reagents, instruments, custom manufacturing, and testing services. Our family of brands creates a unique portfolio of products and services. Science ...
Immune cell therapy is rapidly emerging as an important alternative for cancer treatment, as well as treatment of autoimmune disease. Also known as adoptive cell therapy or cellular immunotherapy, it supercharges an individual’s immune ...
based inRixensart, BELGIUM
CuraVac is a clinical-stage biotech company developing the medical and commercial potential of a revolutionary technique for the production of specific Therapeutic Vaccines for the treatment of autoimmune diseases. The company was founded by a ...
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...
based inMont-Saint-Guibert, BELGIUM
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. We are developing a diversified pipeline of allogeneic and autologous CAR T cell ...
CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patient’s T cells to express both (i) the NKG2D chimeric antigen receptor, a receptor expressed on ...
based inIrvine, CALIFORNIA (USA)
Established in 1997 by a group of renowned scientists, GeneTex's corporate mission remains clear. While commercial polyclonal and monoclonal antibodies have driven progress in science and medicine since their introduction, the generation of reliable ...
![GeneTex - Model CD19 -[HIB19] (PE-Cy7) - Antibody](https://d32zuqhgcrpxli.cloudfront.net/eyJidWNrZXQiOiJlZS1maWxlcyIsImtleSI6ImZpbGVzLzExMzU1Ny9pbWFnZXMvMTEzNTU3XzBfMjAyMDEwMjkwNjExMzA2NzI0ODA1XzQwMC5wbmciLCJlZGl0cyI6eyJyZXNpemUiOnsiZml0IjoiY29udGFpbiIsImJhY2tncm91bmQiOnsiciI6MjU1LCJnIjoyNTUsImIiOjI1NSwiYWxwaGEiOjF9LCJ3aWR0aCI6MTQzLCJoZWlnaHQiOjEwMn19fQ== "GeneTex - Model CD19 -[HIB19] (PE-Cy7) - Antibody")
The HIB19 antibody reacts with human CD19, a 95 kDa glycoprotein which acts as a co-receptor, along with CD21, CD81 and CD225, in support of the functional B cell receptor (BCR). This complex provides ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical ...